An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Pharmacoeconomic Review Report: Crisaborole Ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: For topical treatment of mild-to-moderate atopic dermatitis in patients two years of age and older [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr.
Top results in this bookTable of Contents
Systematic review of treatments for atopic eczema.
Hoare C, Li Wan Po A, Williams H.
Southampton (UK): NIHR Journals Library; 2000 Dec. (Health Technology Assessment, No. 04.37.)
Scoping systematic review of treatments for eczema.
Nankervis H, Thomas KS, Delamere FM, et al.
Southampton (UK): NIHR Journals Library; 2016 May. (Programme Grants for Applied Research, No. 4.7.)
Betamethasone for Adults with Scalp Psoriasis: A Review of the Clinical and Cost-Effectiveness [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Mar 30.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Ruxolitinib (Opzelura): Therapeutic area: Nonsegmental vitiligo: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2026 Feb.
Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults.
Geneva: World Health Organization; 2014.
The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study.
Cro S, Cornelius V, Capon F, et al.
Southampton (UK): NIHR Journals Library; 2022 Mar. (Efficacy and Mechanism Evaluation, No. 9.2.)
Upadacitinib (Rinvoq): CADTH Reimbursement Review: Therapeutic area: Atopic dermatitis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.
A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR, Wojnarowska F, Kirtschig G, et al.
Southampton (UK): NIHR Journals Library; 2017 Mar. (Health Technology Assessment, No. 21.10.)
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2026 Jan-.
Roflumilast (Zoryve): CADTH Reimbursement Review: Therapeutic area: Plaque psoriasis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Edwards SJ, Karner C, Jhita T, et al.
Southampton (UK): National Institute for Health and Care Research; 2024 Jan. (Health Technology Assessment, No. 28.04.)
Abrocitinib (Cibinqo): CADTH Reimbursement Review: Therapeutic area: Atopic dermatitis, moderate to severe [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Duarte A, Mebrahtu T, Goncalves PS, et al.
Southampton (UK): NIHR Journals Library; 2017 Nov. (Health Technology Assessment, No. 21.64.)
Environmental Medicine: Integrating a Missing Element into Medical Education.
Institute of Medicine (US) Committee on Curriculum Development in Environmental Medicine; Pope AM, Rall DP, editors.
Washington (DC): National Academies Press (US); 1995.
Ruxolitinib (Opzelura): Therapeutic area: Atopic dermatitis: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Sep.
Utilization of Old- Versus New-Generation Biologics for Plaque Psoriasis for Public and Private Payers in Canada: Technology Review [Internet].
Dyrda P, Vannabouathong C, Peter K, et al.; Authors.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jun.
Economic model report: Chronic obstructive pulmonary disease in over 16s: diagnosis and management: Evidence review H.
London: National Institute for Health and Care Excellence (NICE); 2018 Dec. (NICE Guideline, No. 115.)
Dupilumab (Dupixent): CADTH Reimbursement Review: Therapeutic area: Atopic dermatitis, pediatrics [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Dec.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on